$IMMX CAR-T NXC-201 late breaking, oral presentation two weeks out. Previous data has been perfection (100% ORR in AL Amyloidosis). Similar to $GRCL, these guys will likely get bought out in next 12-18 months if this kind of data keeps up.
Stifel⬆️ $CABA $32 was $31/Buy~believes if CABA-201 looks in-line w/ other CAR T's, invs will gain > comfort around the IASO-procured CAR T's /Co's ability2generate high efficacy data in US pts; thinks CABA's weak because Co hasn't yet Tx'd an SLE pt.
Co is clearly making progress in Myositis, and per Stifel's convo w/ Mgmt/r confident that they will have SLE data by 1H24.
$grcl $autl $bmy $kytx nvs
$KRON know who you trade with this guy is a baller caller wow!
4 bagger caller biotech $GRCL 2.52 to 10.22 BUYOUT and now he’s saying he wants an 8 bagger from here on $KRON I’m adding more tomorrow now that I’ve scrolled his profile and seen his picks 😮 💰 😮
$KRON this dude knows how to pick biotech winners he got a triple on this pick $GRCL and now he’s excited about another stock being slept on w only 540 watchers, ie $KRON
$GRCL $AZN Gracell Biotechnologies shareholders approved the company’s proposed acquisition by AstraZeneca. The transaction is expected to close on or around February 22.
$GRCL eyeing sept 20, 2024 $12.50 calls, if the buy out happens wouldn’t share price be higher then $12.50? Calls at $0.15 break even $12.65 and buyout was about a 20%+ premium?
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets $SNY $HCM $GRCL https://talkmarkets.com/content/global-markets/week-in-review-shanghai-inmagene-signs-230-million-deal-to-develop-two-hutchmed-immunology-assets?post=430414&userid=123969
